Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 12 of 12

Type	Event	Organ system	Group	Affected	At risk	Events
other	Blood creatine phosphokinase increased	Investigations	IM Olanzapine 10mg	0	17	0
other	Blood creatine phosphokinase increased	Investigations	IM Placebo	1	16	1
other	Blood glucose increased	Investigations	IM Olanzapine 10mg	1	17	1
other	Blood glucose increased	Investigations	IM Placebo	0	16	0
other	Blood pressure increased	Investigations	IM Olanzapine 10mg	1	17	1
other	Blood pressure increased	Investigations	IM Placebo	0	16	0
other	Electrocardiogram T wave inversion	Investigations	IM Olanzapine 10mg	0	17	0
other	Electrocardiogram T wave inversion	Investigations	IM Placebo	1	16	1
other	Glucose urine present	Investigations	IM Olanzapine 10mg	1	17	1
other	Glucose urine present	Investigations	IM Placebo	0	16	0
other	Erythema	Skin and subcutaneous tissue disorders	IM Olanzapine 10mg	1	17	1
other	Erythema	Skin and subcutaneous tissue disorders	IM Placebo	0	16	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00640510/events